Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Common criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:~1. Had completed the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study.~2. Was capable of understanding and complying with protocol requirements.~3. Signed a written informed consent form prior to the initiation of any study procedure.~Exclusion Criteria:~Common criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:~1. With clinical manifestation of hepatic impairment (eg, an aspartate aminotransferase or alanine aminotransferase value of 2.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).~2. With clinical manifestation of renal impairment (eg, a creatinine value of 1.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).~3. With serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease (eg, a subject who requires hospital admission).~Criteria that applied only to participants completing the core phase 2/3 metformin add-on study:~1. With history or symptoms of lactic acidosis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).